In the past 20 years, pharmaceutical and biotechnology industry R&D has been increasingly aimed at developing drugs to treat complex diseases. However, the one drug-one target-one disease paradigm that has become dominant in the post-genomic era has proven to be inadequate to address complex diseases, which have multiple “causes”. Moreover, researchers have found that most of the successful, FDA-approved small-molecule drugs that were developed prior to the year 2000 are promiscuous, i.e., they are single drugs that address multiple targets. The great majority of kinase inhibitors, one of the most successful drug classes of the early 21st century, are also promiscuous.
Meanwhile, the development of targeted drugs such as kinase inhibitors and monoclonal antibodies has resulted in the need to develop multitargeted combination therapies. This has been especially true in cancer, where disease causation may involve multiple signaling pathways. In particular, the development of resistance to targeted antitumor drugs has spawned the need to develop second-generation treatments, many of which are multitargeted combination therapies.
This new Insight Pharma Report covers both discovery and design of small-molecule promiscuous/multitargeted drugs, and of multitargeted combination therapies.
For more information on the report, or to order it, see the CHI Insight Pharma Reports website.
Multitargeted Therapies: Promiscuous Drugs and Combination Therapies
Alan Haberman holds a Ph.D. in biochemistry and molecular biology from Harvard University and has an extensive background in the pharmaceutical and biotechnology industry.
More on the author.
*Report is available for single user, multi-user, single-site, multi-site or for global use.